MDA 2020 abstract: Pulmonary function in non-ambulatory patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) from the STRIDE Registry and CINRG Duchenne Natural History Study: A matched cohort analysis
Get a brief comparison of pulmonary function decline between two matched cohorts of patients with Duchenne muscular dystrophy (DMD) in our abstract presented at MDA 2020
The objectives and approach taken in a matched cohort analysis comparing pulmonary function decline in non-ambulatory nmDMD patients treated with a mutation-specific DMD therapy plus standard of care (SoC; corticosteroid or palliative therapies) and matched patients with DMD receiving SoC alone (Cooperative International Neuromuscular Research Group [CINRG]) Duchenne Natural History Study are presented in this abstract
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at pharmacovigilance@ptcbio.com.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
GL-DMD-0313 | June 2021
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.